Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. United States/
    2. Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma

    Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma

    June 5, 2023
    June 5, 2023

    Download the PDF